Given that SQLE is overexpressed in pancreatic cancer and plays a role in tumor progression through cholesterol metabolism, targeting this enzyme with HCJ007 could lead to reduced tumor growth and improved patient outcomes. This evidence concerns the gene SQLE and neoplasm.